Antiemetic Drug
PreclinicalSmall molecule
Antiemetic Drug is one of 10 small molecule programs targeting Nausea. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Pregnant Women
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
Tirosint
IInstitut Jerome Lejeune
Approved
Tdap Vaccine
SanofiPhase 3
GBS-NN/NN2
MMinervax ApS
Phase 3
Hecolin ).
IInternational Vaccine Institute
Phase 2
IV Acetaminophen
AAFT Pharmaceuticals, Ltd.
Preclinical
Nicotinamide
MMetro International Biotech, LLC
Preclinical
Choline Bitartrate
UUniversity of Minnesota
Preclinical
Antiemetic Drug
UUniversity of West Attica
Preclinical
Shanchol
EEuBiologics Co.,Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Nausea1 trial
Pregnant Women1 trial
Effect of Kinesiotape on Emesis in Pregnant Women
Not yet recruiting·—·N/A·NCT06625632·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antiemetic Drug. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of West Attica